Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

A 2016 study explored the potential of cannabinoids as therapeutic agents for Amyotrophic Lateral Sclerosis (ALS), focusing on their neuroprotective, anti-inflammatory, and antioxidant effects. While promising results were observed in preclinical models, clinical research at the time remained limited, primarily addressing symptom management rather than disease modification. 

In preclinical studies, cannabinoids like Δ9-THC and cannabinol (CBN) demonstrated the ability to reduce oxidative stress, mitigate excitotoxicity, and modulate neuroinflammation in ALS animal models. These effects were linked to the activation of CB2 receptors, which suppressed microglial activation, glutamate release, and reactive oxygen species (ROS) formation. CB2 receptor activation was associated with delayed disease progression and improved motor function in animal studies, though survival benefits varied. 

Clinical investigations reported moderate symptom relief for spasticity, pain, and appetite loss. However, no clinical trials at the time provided evidence of cannabinoids as disease-modifying therapies. The study emphasized the need for further research, particularly in light of the approval of Sativex® (a Δ9-THC and CBD mixture) for other conditions, which highlighted the potential of combination therapies. 

Learn more about this paper and its findings here:   

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? - PMC